Literature DB >> 15501399

Molecular characterization of the OspA(161-175) T cell epitope associated with treatment-resistant Lyme arthritis: differences among the three pathogenic species of Borrelia burgdorferi sensu lato.

Elise E Drouin1, Lisa J Glickstein, Allen C Steere.   

Abstract

Treatment-resistant Lyme arthritis, which may result from infection-induced autoimmunity, is associated with reactivity to a T cell epitope of outer-surface protein A (OspA(161-175)) of Borrelia burgdorferi sensu stricto (Bb). This syndrome has been noted primarily in the United States where only Bb is present, and rarely in Europe where Borrelia garinii (Bg) and Borrelia afzelii (Ba) predominate. To gain a better understanding of this epitope, we identified its species-specific polymorphisms, determined their immunogenicity, and characterized the contribution of individual amino acids. Based on published sequences the Bb peptide differed from the Ba peptide in six of the nine core residues (amino acids 165-173), whereas the Bg peptide usually differed in three of the nine residues. Lymphocytes from seven patients with treatment-resistant Lyme arthritis proliferated in response to the Bb peptide, but not to the Ba or Bg peptide. Substitution analysis showed that valine166 and threonine172 were critical for the immunogenicity of the Bb peptide. Thus, consistent with the geographic distribution of the illness, the European causative agents of Lyme borreliosis usually lack the putative pathogenic OspA epitope. These observations are consistent with the hypothesis that T cell recognition of this epitope is important in the induction of autoimmunity in treatment-resistant Lyme arthritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501399     DOI: 10.1016/j.jaut.2004.06.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  8 in total

1.  Analysis of Borrelia burgdorferi genotypes in patients with Lyme arthritis: High frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis.

Authors:  Kathryn L Jones; Gail A McHugh; Lisa J Glickstein; Allen C Steere
Journal:  Arthritis Rheum       Date:  2009-07

2.  Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice.

Authors:  Joseph Kuo; Dean T Nardelli; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

3.  Broadly Protective Multivalent OspA Vaccine against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment.

Authors:  Abhijeet Nayak; Wolfgang Schüler; Stefan Seidel; Ivan Gomez; Andreas Meinke; Pär Comstedt; Urban Lundberg
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

Review 4.  Relationship between immunity to Borrelia burgdorferi outer-surface protein A (OspA) and Lyme arthritis.

Authors:  Allen C Steere; Elise E Drouin; Lisa J Glickstein
Journal:  Clin Infect Dis       Date:  2011-02       Impact factor: 9.079

5.  Human homologues of a Borrelia T cell epitope associated with antibiotic-refractory Lyme arthritis.

Authors:  Elise E Drouin; Lisa Glickstein; William W Kwok; Gerald T Nepom; Allen C Steere
Journal:  Mol Immunol       Date:  2007-06-06       Impact factor: 4.407

6.  A Bayesian spatio-temporal model for forecasting Anaplasma species seroprevalence in domestic dogs within the contiguous United States.

Authors:  Yan Liu; Stella C Watson; Jenna R Gettings; Robert B Lund; Shila K Nordone; Michael J Yabsley; Christopher S McMahan
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

Review 7.  Treatment of Lyme borreliosis.

Authors:  Hermann J Girschick; Henner Morbach; Dennis Tappe
Journal:  Arthritis Res Ther       Date:  2009-12-17       Impact factor: 5.156

8.  Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a Borrelia burgdorferi peptide.

Authors:  Allen C Steere; William Klitz; Elise E Drouin; Ben A Falk; William W Kwok; Gerald T Nepom; Lee Ann Baxter-Lowe
Journal:  J Exp Med       Date:  2006-04-03       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.